Efficacy and Safety of Dexlansoprazole MR and Lansoprazole on Healing of Erosive Esophagitis
Completed
Takeda
Phase 3
2005-12-01
The purpose of this study is to assess the efficacy and safety of 8 weeks of once-daily (QD)
treatment with dexlansoprazole modified release (MR) 60 mg or 90 mg or lansoprazole 30 mg in
healing subjects with endoscopically proven erosive esophagitis.
Efficacy and Safety of Dexlansoprazole MR and Lansoprazole on Healing of Erosive Esophagitis
Completed
Takeda
Phase 3
2005-12-01
This is a study to assess the efficacy and safety of 8 weeks of treatment with
Dexlansoprazole modified release (MR)(60 mg daily and 90 mg daily) compared to Lansoprazole
(30 mg daily) in healing subjects with endoscopically proven erosive esophagitis.
Efficacy and Safety of Dexlansoprazole Modified Release Formulation to Treat Heartburn
Completed
Takeda
Phase 3
2005-12-01
The purpose of this study is to assess the efficacy and safety of daily treatment with
Dexlansoprazole modified release (MR) (60 mg or 90 mg once daily [QD]) compared to placebo QD
in relief of daytime and nighttime heartburn over 4 weeks in subjects with gastroesophageal
reflux disease (GERD).
Safety and Efficacy of Dexlansoprazole Modified Release Formulation to Treat Heartburn
Completed
Takeda
Phase 3
2005-12-01
The purpose of this study is to assess the efficacy and safety of daily treatment with
Dexlansoprazole modified release (MR) (60 mg or 90 mg once daily [QD]) compared to placebo QD
in relief of daytime and nighttime heartburn over 4 weeks in subjects with gastroesophageal
reflux disease (GERD).
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
